[Second report of XXXX : clinical study].

@entity32 @entity19001 @entity203 @entity344 @entity5274 @entity1271 @entity800
We previously reported a study on the antimicrobial action of a chemically synthesized drug, @entity800 ( @entity19001 ) and on its transfer in. This paper describes the results of our clinical study on @entity19001 . 1. Only small fractions of intra-blood @entity19001 were transported into female organs such as uterus, @entity5274 . Our study with the normal delivery method shows that umbilical cord blood concentrations of @entity19001 is a third to a sixth of maternal blood concentrations and is achieved through trans-placental transfer. Its transfer into amniotic fluid, however, is very low. 2. Forty-one cases, including cases of female intrapelvic @entity32 , urinary tract infection, puerperal @entity1271 , etc., were administered with @entity19001 at levels of 200 approximately 400 mg/day for 3 approximately 10 days. @entity19001 were found to be effective in 35 cases. 3. We observed 113 cases to which @entity19001 was administered, and found only 4 cases of @entity344 and 1 case of suspicion of @entity203 as side effects. Laboratory tests showed no abnormalities due to @entity19001 in blood, serum biochemical or urine value in the cases examined (26 to 51 cases depending on test).
